摘要
目的分析甲状腺癌诊断中联合US-FNAB检查及BRAFV600E基因检测的诊断价值。方法以2018年1月~2019年8月就诊于我院的110例疑似甲状腺癌患者作为观察对象,以术后病理学结果作为诊断金标准,分析US-FNAB联合BRAFV600E基因检测在甲状腺癌诊断中的应用价值。结果US-FNAB检查、BRAFV600E基因检测及US-FNAB联合BRAFV600E基因检测均对甲状腺癌具有明确的诊断价值(P<0.05),但以US-FNAB检查联合BRAFV600E基因检测的诊断价值最高(P<0.05)。结论在甲状腺癌的诊断过程中,可将联合US-FNAB检查联合BRAFV600E基因检测作为诊断指标。
Objective To investigate the diagnostic value of ultrasound-guided fine needle aspiration biopsy(US-FNAB)combined with the detection of BRAFV600E oncogene in thyroid cancer.Methods From January 2018 to August 2019,110 patients with suspected thyroid cancer admitted in our hospital were selected as subjects.Post-operative pathological results were considered as the gold-standard diagnostic criteria.The application value of US-FNAB combined with the BRAFV600E oncogene test in diagnosing thyroid cancer was evaluated.Results US-FNAB,the detection of BRAFV600E oncogene and their combination presented significant diagnostic values in thyroid cancer(P<0.05).However,US-FNAB combined with the detection of BRAFV600E oncogene showed the best performance in the diagnosis(P<0.05).Conclusion US-FNAB combined with the BRAFV600E oncogene test can be included as a diagnostic indicator for thyroid cancer in clinical practices.
作者
卢志荣
LU Zhirong(Department of Ultrasonography,Foshan Sanshui District People's Hospital in Guangdong Province,Foshan528000,China)
出处
《中国现代医生》
2020年第6期135-138,共4页
China Modern Doctor
